Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Chimeric antigen receptor (CAR) T cell therapy shows long-term prospects for patients with the advanced disease by modifying the patient's own immune cells to recognize and attack specific tumors. Since treatment works by using the immune system, off-target activity promotes inappropriate immune responses and is very dangerous to patients.
Therefore, Creative Biolabs has developed Surfarray™ cell microarray technology for labeling and screening whole CAR-T cells, which is widely used to evaluate final engineered cells as well as precursor antibodies / scFv.
Creative Biolabs has two methods for targeted screening of CAR-T cells:
Note: Early specific screening helps to select the right scFv to maximize the chances of producing the most promising potential CAR-T therapy. A more relevant assessment of off-target responsibility can then be provided by screening the entire engineered T cell (or final scFv). Since there may be inconsistencies between the original antibody / scFv and the final engineered T cells, both can be screened to ensure that the binding is not altered during development.
High Specificity
Surfarray™'s low false positive rate ensures that months or years of research are not wasted to chase dead ends when verifying potential target hits. CAR-T cells specificity screening using Surfarray™ cell microarray technology typically reports one or two confirmed interactions, rather than 100 erroneous results often seen by protein microarrays. This saves months of verification and avoids unnecessary groping, which can affect regulatory submissions.
Creative Biolabs is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes.
For more detailed information, please feel free to contact us or directly send us an inquiry.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
